Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Liabilities and Shareholders Equity (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Liabilities and Shareholders Equity data on record, last reported at $52.7 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity changed N/A year-over-year to $52.7 million; the TTM value through Sep 2025 reached $233.3 million, up 95.26%, while the annual FY2024 figure was $97.8 million, 18.11% down from the prior year.
  • Liabilities and Shareholders Equity reached $52.7 million in Q3 2025 per SNTI's latest filing, down from $82.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $231.9 million in Q2 2021 and bottomed at $373657.0 in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $140.3 million, with a median of $137.7 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 61698.89% in 2022, then plummeted 33.91% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $96.7 million in 2021, then surged by 86.96% to $180.8 million in 2022, then crashed by 33.91% to $119.5 million in 2023, then dropped by 18.11% to $97.8 million in 2024, then tumbled by 46.15% to $52.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $52.7 million in Q3 2025, $82.8 million in Q1 2025, and $97.8 million in Q4 2024.